Cargando…
Severe Ulcerative Esophagitis Induced by Crizotinib Therapy
Crizotinib is an oral tyrosine-kinase inhibitor that inhibits anaplastic lymphoma kinase (ALK) in gene-rearranged non-small cell lung cancer (NSCLC). In 2011, the Food and Drug Administration approved crizotinib for treatment of locally advanced or metastatic ALK-positive NSCLC. The crizotinib adver...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American College of Gastroenterology
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4435292/ https://www.ncbi.nlm.nih.gov/pubmed/26157832 http://dx.doi.org/10.14309/crj.2014.8 |
_version_ | 1782371893114830848 |
---|---|
author | Jalil, Ala' A Abdel Craig, Jamie Bajaj, Rajesh Spurling, Timothy |
author_facet | Jalil, Ala' A Abdel Craig, Jamie Bajaj, Rajesh Spurling, Timothy |
author_sort | Jalil, Ala' A Abdel |
collection | PubMed |
description | Crizotinib is an oral tyrosine-kinase inhibitor that inhibits anaplastic lymphoma kinase (ALK) in gene-rearranged non-small cell lung cancer (NSCLC). In 2011, the Food and Drug Administration approved crizotinib for treatment of locally advanced or metastatic ALK-positive NSCLC. The crizotinib adverse events profile included esophageal disorders in 11% of patients treated during trial phases I, II, and III, but none of them had severe events. We describe the development of severe ulcerative esophagitis secondary to crizotinib therapy and the re-introduction of therapy at a lower dose without recurrence of esophageal symptoms. |
format | Online Article Text |
id | pubmed-4435292 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | American College of Gastroenterology |
record_format | MEDLINE/PubMed |
spelling | pubmed-44352922015-07-08 Severe Ulcerative Esophagitis Induced by Crizotinib Therapy Jalil, Ala' A Abdel Craig, Jamie Bajaj, Rajesh Spurling, Timothy ACG Case Rep J Case Report Crizotinib is an oral tyrosine-kinase inhibitor that inhibits anaplastic lymphoma kinase (ALK) in gene-rearranged non-small cell lung cancer (NSCLC). In 2011, the Food and Drug Administration approved crizotinib for treatment of locally advanced or metastatic ALK-positive NSCLC. The crizotinib adverse events profile included esophageal disorders in 11% of patients treated during trial phases I, II, and III, but none of them had severe events. We describe the development of severe ulcerative esophagitis secondary to crizotinib therapy and the re-introduction of therapy at a lower dose without recurrence of esophageal symptoms. American College of Gastroenterology 2014-01-10 /pmc/articles/PMC4435292/ /pubmed/26157832 http://dx.doi.org/10.14309/crj.2014.8 Text en Copyright © Abdel Jalil et al. This is an open-access article. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ |
spellingShingle | Case Report Jalil, Ala' A Abdel Craig, Jamie Bajaj, Rajesh Spurling, Timothy Severe Ulcerative Esophagitis Induced by Crizotinib Therapy |
title | Severe Ulcerative Esophagitis Induced by Crizotinib Therapy |
title_full | Severe Ulcerative Esophagitis Induced by Crizotinib Therapy |
title_fullStr | Severe Ulcerative Esophagitis Induced by Crizotinib Therapy |
title_full_unstemmed | Severe Ulcerative Esophagitis Induced by Crizotinib Therapy |
title_short | Severe Ulcerative Esophagitis Induced by Crizotinib Therapy |
title_sort | severe ulcerative esophagitis induced by crizotinib therapy |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4435292/ https://www.ncbi.nlm.nih.gov/pubmed/26157832 http://dx.doi.org/10.14309/crj.2014.8 |
work_keys_str_mv | AT jalilalaaabdel severeulcerativeesophagitisinducedbycrizotinibtherapy AT craigjamie severeulcerativeesophagitisinducedbycrizotinibtherapy AT bajajrajesh severeulcerativeesophagitisinducedbycrizotinibtherapy AT spurlingtimothy severeulcerativeesophagitisinducedbycrizotinibtherapy |